S
spotitearly
Develops scent based multi-cancer early detection screening test, combining bio detectors together with proprietary AI stack, to save people’s lives
About spotitearly
Spotitearly.com is a promising startup operating in the healthcare sector, specifically in the field of cancer detection. The company is developing a groundbreaking multi-cancer early detection test that is both affordable and easy to use. The technology behind this test is designed to detect multiple types of cancer at once, including breast, lung, colon, and prostate cancer.
The company's business model is centered on the development and commercialization of this early detection test. The test is currently in the clinical trial phase, with results indicating higher sensitivity and better specificity in detecting early stages of cancer compared to existing tests on the market. This suggests that Spotitearly's product could potentially revolutionize the cancer detection market by providing a more accurate and cost-effective solution.
The company's target clients are primarily healthcare providers and patients who are at risk of developing cancer. By offering an affordable and easy-to-use test, Spotitearly aims to make early cancer detection accessible to a wider population, thereby potentially saving lives and reducing healthcare costs.
The company's revenue model is likely to be based on the sales of these tests to healthcare providers and patients. Given the high prevalence of cancer and the critical importance of early detection, the market potential for Spotitearly's product is significant.
In summary, Spotitearly is a healthcare startup focused on revolutionizing cancer detection through an innovative, affordable, and easy-to-use multi-cancer early detection test.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 75.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, medical testing
- Technology
- Artificial Intelligence
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | May 2025 | $20M | $81M | Avishai Abrahami · Menomadin Foundation · Hanaco Venture Capital | ↗ |
| EARLY VC✓Equity / VC | Nov 2023 | $7.8M | $31M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for spotitearly is 5.4K monthly website visits, down 12.9% over the last three months. spotitearly's team grew 3.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Hanaco Venture Capital
Michael Eisenberg- JSJeff Schwartz
Series A2 investors entered at this stage
Avishai Abrahami
Menomadin Foundation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about spotitearly on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See spotitearly’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







